Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.

The mechanistic target of rapamycin (mTOR) is an established therapeutic target in renal cell carcinoma (RCC). Mechanisms of secondary resistance to rapalog therapy in RCC have not been studied previously. We identified six patients with metastatic RCC who initially responded to mTOR inhibitor thera...

Descripció completa

Dades bibliogràfiques

Autors principals:	Lana Hamieh, Toni K Choueiri, Barbara Ogórek, Damir Khabibullin, Daniel Rosebrock, Dimitri Livitz, Andre Fay, Jean-Christophe Pignon, David F McDermott, Neeraj Agarwal, Wenhua Gao, Sabina Signoretti, David J Kwiatkowski
Format:	Artigo
Idioma:	Inglês
Publicat:	Public Library of Science (PLoS) 2018-09-01
Col·lecció:	PLoS Genetics
Accés en línia:	https://hdl.handle.net/10923/21647
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!